SAN DIEGO, March 30 /PRNewswire/ -- Cyntellect, Inc., a privately-held biotechnology company, today announced the company has entered into a research agreement with Daiichi Pharmaceutical Co., Ltd. ("Daiichi") to utilize Cyntellect's high-throughput cell imaging and laser-based cell manipulation technology, LEAP(TM), for novel drug discovery.
Under the terms of the collaboration, Cyntellect will design, configure and run LEAP cell-based assays against a compound collection provided by Daiichi. Specific financial terms were not disclosed.
"We are pleased to establish a formal research relationship with Daiichi, one of Japan's leading pharmaceutical companies," stated Dr. Fred Koller, President and CTO. "Daiichi's commitment to Cyntellect and LEAP represents another important validation of our technology and highlights the unique value proposition presented by combining imaging and cell manipulation in the process of discovering new therapeutics."
About Daiichi Pharmaceuticals, Co. Ltd.
Daiichi Pharmaceutical Co., Ltd., has been a leader in the Japanese pharmaceutical industry for nearly a century. Established in 1918, the Company has grown as a research and development (R&D) based organization, ensuring its leading position as a developer of advanced pharmaceutical products and health care related chemicals for nearly 90 years. Daiichi Pharmaceutical continues to contribute to the pharmaceutical industry by creating products that improve health and promote longer and happier lives.
Cyntellect, Inc. is a biotechnology company committed to revolutionizing the use of living cells in life sciences research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at http://www.cyntellect.com/.
CONTACT: Jim Linton, Ph.D., Chief Business Officer of Cyntellect, Inc.,+1-858-450-7060, email@example.com